OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • 2024 nominations are open for Giants of Cancer Care®
  • In-person and virtual events just for HCPs
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
Advertisement

Shari Mycek

home / authors / shari-mycek

Articles

Advertisement

Peter Martin, MD

Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

June 12th 2021

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Read More


Breast cancer

Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer

June 6th 2021

The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Read More


Giuseppe Curigliano, MD, PhD, associate professor of medical oncology at the University of Milano and the head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy

Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer

June 5th 2021

Tucatinib plus trastuzumab and capecitabine maintained and even improved overall survival over placebo in pretreated patients with HER2-positive breast cancer.

Read More


Salma K. Jabbour, MD

Concurrent Pembrolizumab Plus Chemoradiation Therapy Elicits Antitumor Activity in NSCLC

June 4th 2021

Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.

Read More

Latest Conference Coverage

Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact